Our breakthrough findings on B. infantis EVC001 and its impacts on infant health have been addressed in notable publications around the world.
We are pleased to announce that our company has changed its name from Evolve Biosystems to Infinant Health™—a life sciences company. Rest assured, our flagship product, Evivo, will not be changing. Neither will our focus on infant health, as we continue to improve gut health and support healthy immune system function.
Prospective study designed to assess the immunological effect of a specific B. infantis strain on the incidence of atopic dermatitis, one of the most prevalent pediatric allergic diseases.
Former Infinant Health, Inc Board Member Mike Johnson will lead the company as it continues to spearhead innovative advancements in science surrounding infant health
Together, CWWDA and Infinant Health will demonstrate the power of promoting health care from birth, rather than disease care later.
Study aims to investigate whether infant probiotic Evivo can reduce development of early childhood atopic dermatitis.
Researchers in Beneficial Microbes reported that three common infant health issues associated with Newborn Gut Deficiency were reduced or eliminated altogether within days of introducing a key beneficial gut bacterium.
Study Published in Journal of Pediatrics Discusses Potential for Improved Clinical Care Associated with Administration of B. infantis EVC001 in Very Low Birth Weight Infants